Clinical and genetic characteristics of patients with chronic enteropathy associated with SLCO2A1 gene
10.3760/cma.j.cn112138-20200318-00259
- VernacularTitle:SLCO2A1基因相关慢性肠病临床特点及遗传学特征分析
- Author:
Qiang WANG
;
Hui XU
;
Yue LI
;
Yaping LIU
;
Dong WU
;
Weixun ZHOU
;
Hong YANG
;
Weibo XIA
;
Jiaming QIAN
- From:
Chinese Journal of Internal Medicine
2021;60(1):45-50
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To determine the clinical features and genetic characters of patients with chronic enteropathy associated SLCO2A1 gene (CEAS). Methods:Five CEAS patients diagnosed at Peking Union Medical College Hospital from January 2012 to December 2019 were enrolled in this study. The clinical manifestations, laboratory test, radiological and endoscopic findings, gene detections, treatments and prognosis of these patients were reviewed and analyzed.Results:Five male patients presented gastrointestinal symptoms after puberty, including abdominal pain, diarrhea, intermittent melena or hematochezia, incomplete bowel obstruction, anemia, hypoalbuminemia and hypokalemia. The whole gastrointestinal tract except esophagus could be involved, especially the stomach and ileum. Intestinal lesions were characterized by multiple shallow ulcers with stenosis in the layers of mucosa and submucosa. Five patients were all accompanied with primary hypertrophic osteoarthropathy (PHO), and 1 with myelofibrosis and thoracic duct dysplasia. All patients were homozygous or compound heterozygous mutations of SLCO2A1 gene. Conventional treatment of inflammatory bowel disease and COX-2 inhibitors were ineffective. Conclusions:CEAS is an autosomal recessive genetic disease which widely involves the gastrointestinal tract, and can be associated with skin and bone involvement. There is no effective treatment for CEAS at present. CEAS is a different entity from other inflammatory gastrointestinal diseases.
